Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Randomized Trial of the I-BFM-SG for the Management of Childhood non-mature-B Acute Lymphoblastic Leukemia (ALLIC 2022)
2024-513824-41-00Phase 4Authorised
- Sponsor
- Semmelweis University
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 4, randomised trial in acute lymphoblastic leukemia (ALL) comparing Rituximab + intensive chemotherapy including pegaspargase with Intensive chemotherapy including pegaspargase (control) (2 arms). Primary endpoint: Event-free survival (EFS). Planned start Dec 2024; status: authorised.
02
Drugs
rituximabpegaspargase
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2024-513824-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513824-41-00.